Trilogy-3
Multiple myeloma
A Phase 2, single-arm study of ramantamig
(JNJ-79635322) in relapsed or refractory MM
Phase
Compound
Ramantamig (BCMA × GPRC5D × CD3 trispecific Ab)
NCT identifier
NCT07266441
Enrollment
N=~157
For more information, including
contact details, please visit
the J&J Clinical Trial Finder
contact details, please visit
the J&J Clinical Trial Finder
Study overview & design
Key eligibility criteria*:
- ≥3 prior lines
- Triple-class exposed (PI, iMiD, anti-CD38 mAb)
Study
design
Primary outcomes:
- ORR
Secondary outcomes:
- VGPR or better
- CR or better
- DOR
- PFS
- OS
- TTNT
*Not a complete list of inclusion and exclusion criteria.
CR, complete response; DOR, duration of response; iMiD, immunomodulatory drug; mAb, monoclonal antibody; MM, multiple myeloma; ORR, overall response rate; OS, overall survival; PFS, progression-free survival; PI, proteasome inhibitor; SC, subcutaneous; TTNT, time to next line of therapy; VGPR, very good partial response.